<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; platforms</title>
	<atom:link href="http://www.tapanray.in/tag/platforms/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Focus More To Create Patient-Perceived Value of Brand Outcomes</title>
		<link>http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-more-to-create-patient-perceived-value-of-brand-outcomes</link>
		<comments>http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/#comments</comments>
		<pubDate>Mon, 01 Nov 2021 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2021]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[age]]></category>
		<category><![CDATA[brand outcomes]]></category>
		<category><![CDATA[changes]]></category>
		<category><![CDATA[channels]]></category>
		<category><![CDATA[Complex]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[create]]></category>
		<category><![CDATA[criticality]]></category>
		<category><![CDATA[deliver]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[group]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[older]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[perceived]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10603</guid>
		<description><![CDATA[Healthcare providers, including many drug companies aim to create a beneficial effect on patients with their respective products and services. However, and more importantly, these benefits need to be such that recipients are able to sense, feel, and perceive as &#8230; <a href="http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>More Challenges For Brand Launch Success In The New Normal</title>
		<link>http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=more-challenges-for-brand-launch-success-in-the-new-normal</link>
		<comments>http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/#comments</comments>
		<pubDate>Mon, 08 Feb 2021 00:00:30 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[factors]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insights]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[orchestrators]]></category>
		<category><![CDATA[outcome]]></category>
		<category><![CDATA[patient-centric]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pivotal]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[primary care]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reps]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[success]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tools]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10407</guid>
		<description><![CDATA[The drug manufacturers’ life blood to drive business growth has always been successful new product launch. However, this task has always remained a tough challenge to crack, since last so many years for various reasons. According to McKinsey &#38; Company: “About two-thirds of drug &#8230; <a href="http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/more-challenges-for-brand-launch-success-in-the-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Changing Doctors’ Practice Dynamics With Covid-19 And Beyond</title>
		<link>http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=changing-doctors-practice-dynamics-with-covid-19-and-beyond</link>
		<comments>http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/#comments</comments>
		<pubDate>Mon, 11 May 2020 00:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[channels]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[connected]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[dynamic]]></category>
		<category><![CDATA[face-to-face]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Outbreak]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[practice]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10067</guid>
		<description><![CDATA[Unexpectedly, the answer to an onerous question surfaced just around a year’s time. In my article on this blog, written on April 08, 2019, I raised a question &#8211; “Would ‘Connected Healthcare’ Catch Pharma Players Off-Guard?” Interestingly, an unexpected and abrupt turn of &#8230; <a href="http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Sales Post Covid-19 Lockdown</title>
		<link>http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-sales-post-covid-19-lockdown</link>
		<comments>http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/#comments</comments>
		<pubDate>Mon, 04 May 2020 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[customer-centricity]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[fallout]]></category>
		<category><![CDATA[habit]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[long]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[oldest]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[post Covid-19]]></category>
		<category><![CDATA[preferences]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[selling]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[years]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10054</guid>
		<description><![CDATA[Disruptions from Covid-19 pandemic have caused limited access to physicians for Pfizer&#8217;s marketing and sales teams have had. If ‘the novel Coronavirus pandemic hamstringing the company’s sales team,’ there could be a slowdown in new prescriptions and a sales hit in the second quarter, said the global &#8230; <a href="http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Post Covid-19 Lockdown: Is Pharma Industry Ready?</title>
		<link>http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=post-covid-19-lockdown-is-pharma-industry-ready</link>
		<comments>http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/#comments</comments>
		<pubDate>Mon, 27 Apr 2020 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[customer-centric]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[distancing]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[herd-immunity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[Oxford]]></category>
		<category><![CDATA[physical]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ready]]></category>
		<category><![CDATA[remdesivir]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Social-distancing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[University]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10033</guid>
		<description><![CDATA[It’s over a month now since national lockdown in India came into force to win the war against Covid-19. Many promises and apprehensions about whether or not Covid-19 will keep ravaging human life, continue surfacing. As it appears today, whatever &#8230; <a href="http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/post-covid-19-lockdown-is-pharma-industry-ready/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Disruptive Impact of AI on Pharma Sales And Marketing</title>
		<link>http://www.tapanray.in/disruptive-impact-of-ai-on-pharma-sales-and-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=disruptive-impact-of-ai-on-pharma-sales-and-marketing</link>
		<comments>http://www.tapanray.in/disruptive-impact-of-ai-on-pharma-sales-and-marketing/#comments</comments>
		<pubDate>Mon, 15 Jul 2019 00:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[applications]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[creative]]></category>
		<category><![CDATA[Disruptive]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[KOL]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[people]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[replace]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[tools]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[transformative]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9629</guid>
		<description><![CDATA[Artificial Intelligence (AI) that refers to the ability of machines to perform cognitive tasks like thinking, perceiving, learning, problem solving and decision making, is poised to disrupt our world. Initially conceived as a technology that could mimic human intelligence, AI &#8230; <a href="http://www.tapanray.in/disruptive-impact-of-ai-on-pharma-sales-and-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/disruptive-impact-of-ai-on-pharma-sales-and-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Pharma Communication In Sync With Doctors’ Expectations?</title>
		<link>http://www.tapanray.in/is-pharma-communication-in-sync-with-doctors-expectations/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-pharma-communication-in-sync-with-doctors-expectations</link>
		<comments>http://www.tapanray.in/is-pharma-communication-in-sync-with-doctors-expectations/#comments</comments>
		<pubDate>Mon, 13 May 2019 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[allocation]]></category>
		<category><![CDATA[bridging]]></category>
		<category><![CDATA[channels]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[disconnect]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[gaps]]></category>
		<category><![CDATA[in-sync]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Information]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[monitoring]]></category>
		<category><![CDATA[non-personal]]></category>
		<category><![CDATA[outreach]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Resource]]></category>
		<category><![CDATA[Survey]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[worldwide]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9527</guid>
		<description><![CDATA[Not many pharma companies, especially in India, undertake any ongoing data-based analysis to gain insight on expectations and change in behavioral pattern of their customers, particularly doctors and patients. Many developments are taken as obvious, such as, when busy practitioners &#8230; <a href="http://www.tapanray.in/is-pharma-communication-in-sync-with-doctors-expectations/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-pharma-communication-in-sync-with-doctors-expectations/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Multichannel Marketing: Two Important Pharma Trends</title>
		<link>http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=multichannel-marketing-two-important-pharma-trends</link>
		<comments>http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/#comments</comments>
		<pubDate>Mon, 10 Sep 2018 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[dinner]]></category>
		<category><![CDATA[importance]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCM]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[meetings]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[print]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relevant]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9149</guid>
		<description><![CDATA[On September 6, 2018, Reuters reported the announcement of GlaxoSmithKline (GSK) that it would cut about 650 positions in the United States related to a global restructuring program. This includes 450 Medical (sales) Representatives (MR). Similar announcements on job cuts for MRs &#8230; <a href="http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/multichannel-marketing-two-important-pharma-trends/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Patient-Centricity: Emerging a C-Suite Role</title>
		<link>http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-patient-centricity-emerging-a-c-suite-role</link>
		<comments>http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/#comments</comments>
		<pubDate>Mon, 20 Aug 2018 00:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[attributes]]></category>
		<category><![CDATA[C-suite]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[centricity]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[consistently]]></category>
		<category><![CDATA[CPO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[LEO]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[multi-channel]]></category>
		<category><![CDATA[Officer]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pillars]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9110</guid>
		<description><![CDATA[Regardless of skepticism of many, the formidable power of physicians to take all treatment decisions for patients, is gradually getting moderated, globally. Although, its pace may vary from country to country. An increasing number of more informed patients are carving &#8230; <a href="http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-patient-centricity-emerging-a-c-suite-role/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Indian Pharma To Stay Ahead of The Technology Curve</title>
		<link>http://www.tapanray.in/indian-pharma-to-stay-ahead-of-the-technology-curve/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-pharma-to-stay-ahead-of-the-technology-curve</link>
		<comments>http://www.tapanray.in/indian-pharma-to-stay-ahead-of-the-technology-curve/#comments</comments>
		<pubDate>Mon, 22 May 2017 00:00:23 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Ahead]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[applications]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Chatbot]]></category>
		<category><![CDATA[curve]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[humanoids]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[patient-centric]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[representatitves]]></category>
		<category><![CDATA[shift]]></category>
		<category><![CDATA[staying]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[tools]]></category>
		<category><![CDATA[virtual]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8236</guid>
		<description><![CDATA[In the ever-changing business environment, many industrial sectors have now started leveraging different cutting-edge technological platforms to improve overall strategic and operational effectiveness, keeping a sharp focus on better stakeholder engagement for greater customer satisfaction. These companies have accepted the &#8230; <a href="http://www.tapanray.in/indian-pharma-to-stay-ahead-of-the-technology-curve/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-pharma-to-stay-ahead-of-the-technology-curve/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
